X4 Pharmaceuticals(XFOR)
BOSTON, MAPharmaceutical
Focus: X4 Pharmaceuticals is a Boston-based public biotech focused on oral small molecules targeting rare immunological and oncological diseases. The company operates as a clinical-stage developer with a lean pipeline primarily anchored on Mavorixafor.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at X4 Pharmaceuticals?
AI assessmentX4 is a capital-constrained, clinical-stage biotech suitable only for risk-tolerant professionals betting on Mavorixafor's Phase 3 success and willing to accept potential restructuring or acquisition scenarios.
Why Work Here
- Rare disease focus (WHIM Syndrome, neutropenia) offers meaningful therapeutic impact in underserved patient populations
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$0K
Pipeline & Clinical Trials
No intervention
WHIM SyndromeClinical Trials (1)
NCT03087370A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome
N/AHelp build intelligence for X4 Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.